Search Results
Your search for all items matches 32923 pages
Showing 201 - 250Variations in Use of Radiotherapy in Patients With Newly Diagnosed Common Cancers
In an International Cancer Benchmarking Partnership study reported in The Lancet Oncology, McPhail et al found wide interjurisdictional variation in the use of radiotherapy among patients with newly diagnosed common cancers in Norway, the United Kingdom, Canada, and Australia. Study Details The...
Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL: New Efficacy Analysis
A new matching adjusted indirect comparison of the efficacy of zanubrutinib vs acalabrutinib in relapsed or refractory chronic lymphocytic leukemia (CLL) based on data from the phase III ALPINE and ASCEND trials was presented by Shadman et al at the 28th Annual International Congress on Hematologic ...
Worsening Metabolic Syndrome May Increase Cancer Risk
Investigators may have identified a heightened risk of various types of cancers among patients with persistent and worsening metabolic syndrome, according to a recent study published by Deng et al in Cancer. Background Metabolic syndrome encompasses conditions such as high blood pressure, elevated...
Higher BMI May Be Linked to Complications Following Autologous Breast Reconstruction
Patients with a higher body mass index (BMI) may have a greater risk of overall and specific complications following autologous breast reconstruction, according to a recent study published by Barnes et al in Plastic and Reconstructive Surgery. Background Autologous breast reconstruction—an...
ASCO Chief Medical Officer Testifies to Congress About Ongoing Cancer Drug Shortage Crisis
On February 6, 2024, Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of the Association for Clinical Oncology (ASCO), testified before the full House Committee on Ways and Means on the crisis of ongoing cancer drug shortages. More than 15 cancer drugs continue...
ASCO and SSO Publish New Guideline on Germline Testing in Breast Cancer
ASCO in partnership with the Society of Surgical Oncology (SSO) has released a new guideline addressing recommendations in germline testing in patients with breast cancer.1 The guideline provides oncologists with a framework for how to approach germline testing and recommendations for who should be ...
Patricia LoRusso, DO, PhD (hc), Named the Amy and Joseph Perella Professor of Medicine at Yale School of Medicine
Patricia LoRusso, DO, PhD (hc), an internationally recognized expert in drug development and early-phase clinical investigation of novel cancer therapies, was recently appointed the Amy and Joseph Perella Professor of Medicine (medical oncology). The appointment is for a term of 10 years,...
Expert Point of View: Rachid Baz, MD
DREAMM-7, which evaluated belantamab mafodotin-blmf, bortezomib, and dexamethasone (BVd) in relapsed or refractory multiple myeloma, was discussed at the virtual session by Rachid Baz, MD, Myeloma Section Head and Co-Director of the Pentecost Family Myeloma Research Center at Moffitt Cancer Center, ...
ACCC Changes Name to Association of Cancer Care Centers
The Association of Community Cancer Centers (ACCC) is marking its 50th anniversary with a name change to illustrate the dynamic future of cancer care for its members. The largest advocacy and resource organization for multidisciplinary oncology professionals will now be known as the Association of...
Geriatric Oncology Educational Opportunity at Memorial Sloan Kettering Cancer Center
Once again, geriatric oncology will take the forefront at Memorial Sloan Kettering (MSK). On April 23, 2024, the Division of Advanced Practice Providers and the Geriatric Medicine Service at MSK will host the 3rd annual Geriatric Oncology Symposium for Advanced Practice Providers. The target...
I Am Young and Fit—and Have Stage IV Alveolar Soft-Part Sarcoma
Except for my right thigh being bigger than my left thigh, there was no hint that I was harboring advanced alveolar soft-part sarcoma when I was diagnosed with the cancer in 2019. I initially chocked up the discrepancy in my legs to the vigorous workouts I had received during my cheerleading days,...
Benefit of Belantamab Mafodotin–Based Regimen Supported in Multiple Myeloma
Positive results with the use of belantamab mafodotin-blmf in the phase III DREAMM-7 study were presented during the ASCO Plenary Series: February 2024.1 In relapsed or refractory multiple myeloma, DREAMM-7 evaluated the use of the regimen belantamab mafodotin, bortezomib, and dexamethasone (BVd)...
Fruquintinib in Refractory Metastatic Colorectal Cancer
On November 8, 2023, fruquintinib (Fruzaqla) was approved for adults with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and—if RAS wild-type and medically appropriate—an anti-EGFR therapy.1 Supporting...
How The Max Foundation Is Accelerating Equitable Cancer Care Globally
When Pat Garcia-Gonzalez’ stepson, Max, was diagnosed with chronic myeloid leukemia (CML) in 1988 at the age of 14, the Internet was still in its infancy and decades away from the networking resource it has become today. Told that Max would need an allogeneic stem cell transplant to survive, the...
Expert Point of View: Kim N. Chi, MD
Formal discussant of the BRCAAway trial, Kim N. Chi, MD, of the British Columbia Cancer–Vancouver Center, University of British Columbia, Canada, said this study supports the use of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and homologous recombination–repair...
Olaparib Plus Abiraterone and Prednisone Improves Outcomes Over Single Agents in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
First-line treatment with the PARP inhibitor olaparib plus the androgen biosynthesis inhibitor abiraterone acetate and the steroid prednisone improved progression-free survival and response rates compared with either treatment alone (ie, olaparib or abiraterone plus prednisone) in patients with...
Relationship Between Second Malignant Neoplasm and Heart Disease Studied in Childhood Cancer Survivors
In a French study of more than 7,000 childhood cancer survivors, published in JACC: CardioOncology, Thibaud Charrier, PhD, of the Université Paris-Saclay, Villejuif, France, and colleagues reported that the occurrence of a second malignant neoplasm among these childhood cancer survivors seemed to...
Newly Diagnosed Multiple Myeloma
“Ask yourself at every moment, ‘Is this necessary?’” —Marcus Aurelius To complement The ASCO Post’s extensive coverage of the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two important abstracts selected from the meeting proceedings focusing on induction and...
Long-Term Follow-up Affirms Benefit of Pembrolizumab Plus Chemotherapy in Advanced Esophageal Cancer
Long-term follow-up of the phase III KEYNOTE-590 trial confirms the benefit of the PD-1 inhibitor pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median of follow-up of almost 59 months, patients treated with the chemoimmunotherapy...
Expert Point of View: Michael Crump, MD
Michael Crump, MD, of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, expressed some concerns about the study presented by Shadman et al in patients with large B-cell lymphoma (LBCL). “These data should be interpreted with caution. The patient...
Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?
For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...
Expert Point of View: Aparna R. Parikh, MD
he latest findings for circulating tumor DNA (ctDNA) in colorectal cancer were discussed at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium by Aparna R. Parikh, MD, a gastrointestinal oncologist at Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard...
Studies Show Progress in Using ctDNA to Guide Colorectal Cancer Treatment
Circulating tumor DNA (ctDNA) has become an established biomarker of measurable or molecular residual disease (MRD) after curative-intent surgery in patients with colorectal cancer. The research focus is now on linking ctDNA to long-term outcomes and using it to guide treatment decisions—which was...
Expert Point of View: Alan P. Venook, MD, FASCO
For perspective on CheckMate 8HW, The ASCO Post interviewed Alan P. Venook, MD, FASCO, the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California San Francisco and the Shorenstein Associate Director for Program Development at the Helen...
Nivolumab Plus Ipilimumab Improves Progression-Free Survival in First-Line Setting of Metastatic Colorectal Cancer
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) nonresectable or metastatic colorectal cancer derived significant benefit from an immunotherapy doublet, with nivolumab plus ipilimumab reducing the...
Expert Point of View: Pedro Barata, MD, MSc, FACP
Invited discussant of KEYNOTE-564, Pedro Barata, MD, MSc, FACP, of the University Hospital Seidman Cancer Center, Cleveland, said the reasons for the disparate results in these two adjuvant trials of checkpoint inhibitors were likely the result of many factors. “Factors such as histology, different ...
Two Adjuvant Therapy Studies Show Divergent Outcomes With PD-1 Inhibitors in Renal Cell Carcinoma
In the third prespecified interim analysis of the phase III KEYNOTE-564 trial,1 adjuvant treatment with the PD-1 inhibitor pembrolizumab significantly improved overall survival compared with placebo in patients with intermediate- or high-risk clear cell renal cell carcinoma (RCC). However, a...
Esophageal Squamous Cell Cancer: Overall Survival Improved With Tiragolumab and Atezolizumab Plus Chemotherapy
For patients with treatment-naive, locally advanced or metastatic esophageal squamous cell carcinoma, the addition of two checkpoint inhibitors to chemotherapy significantly improved not only progression-free survival but also overall survival, in the randomized, phase III SKYSCRAPER-08 trial...
Novel MDM2 Inhibitor for Salivary Gland Cancers
A novel MDM2 inhibitor, APG-115 (alrizomadlin), has demonstrated antitumor activity and good tolerability in patients with progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented by Swiecicki et al at the 2024 Multidisciplinary Head and Neck Cancers Symposium ...
Primary Tumor Resection Before Chemotherapy in Patients With Colon Cancer and Unresectable Metastases
In a pooled analysis reported in the Journal of Clinical Oncology, Rahbari et al found that primary tumor resection before chemotherapy did not extend survival compared with upfront chemotherapy in patients with colon cancer and unresectable metastases. Study Details The study involved data from...
Five New Cancer Grand Challenges Teams Named in Global Effort to Resolve Hurdles in Cancer Research
The Cancer Grand Challenges initiative announced it has selected five new global teams that will each receive up to $25 million in funding over the course of 5 years to address four major challenges faced by cancer research. Background In March 2023, the initiative unveiled nine new challenges to...
Inherited Genetic Factors May Influence Risk of Subsequent Cancer Diagnoses in Childhood Cancer Survivors
Investigators have found that common inherited genetic factors capable of predicting cancer risk in the general population may also help to predict childhood cancer survivors who may be at elevated risk of new cancers later in life, according to a recent study published by Gibson et al in Nature...
FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
On March 7, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule BTK inhibitor zanubrutinib (Brukinsa) in combination with the anti-CD20 monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of ...
FDA Approves Nivolumab in Combination With Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma
On March 6, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. CheckMate 901 Efficacy was evaluated in CheckMate ...
Topical Diclofenac to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast or gastrointestinal cancer who were ...
Patients With Early-Stage HR-Positive Breast Cancer May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Newly published study results revealed that use of the Breast Cancer Index (BCI) test led to physicians changing their long-term antiestrogen treatment recommendations for 40% of patients with early-stage hormone receptor–positive breast cancer. The results, which suggest that many women may be...
Physician Attitudes Toward 2020 ACS Cervical Cancer Screening Guidelines
Investigators have uncovered that despite low adoption rates of the 2020 American Cancer Society (ACS) cervical cancer screening guidelines among physicians, a majority of them expressed willingness to utilize the recommendations under certain circumstances, according to a recent study published by ...
Finding New Therapeutic Targets for Male Breast Cancer
Researchers have uncovered distinct alterations in the tumor genome of male patients with breast cancer that may suggest potential therapeutic targets, according to a recent study published by Assaad et al in Modern Pathology. Background Breast cancer in male patients represents less than 1% of all ...
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
On March 6, the U.S. Food and Drug Administration (FDA) approved the CD22-targeted antibody-drug conjugate inotuzumab ozogamicin (Besponsa) for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Study WI203581...
Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report
Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC), selected patients...
Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer
Samuel Regan, MD, and Benjamin Rosen, PhD, both of the University of Michigan, discuss results from a phase II trial showing the possibility of de-escalating chemoradiation treatment for patients with HPV-related oropharyngeal cancer, based on an FDG-PET imaging biomarker. The data suggest that...
Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance
Eleni M. Rettig, MD, of Brigham and Women’s Hospital, discusses the promising but thus far limited data on using circulating tumor HPV DNA for early detection of HPV-related oropharyngeal cancers, which highlights the importance of developing a reliable biomarker (Poster Abstract 177).
Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer
Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses the results of the NDURE study, which explored the delays in starting postoperative radiation therapy in patients with head and neck cancer and ways to improve the timeliness and equity of treatment. Delays in this...
Factors Associated With Myeloid Neoplasms Following CAR T-Cell Therapy
In an analysis reported in a research letter in JAMA Oncology, Gurney et al identified factors associated with an increased risk of myeloid neoplasms after chimeric antigen receptor (CAR) T-cell therapy. Study Details Investigators identified adults who received CAR T-cell therapy between June 2016 ...
Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors
Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses body image distress, a source of significant morbidity among head and neck cancer survivors. He recommends strategies to identify this side effect, the evidence for how best to treat, and best practices to help...
Novel CD123-Targeting Antibody-Drug Conjugate in Relapsed or Refractory AML
In a phase I/II study reported in The Lancet Oncology, Naval Daver, MD, and colleagues found that pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, showed activity in patients with CD123-positive relapsed or refractory acute myeloid leukemia (AML). Study Details...
Low-Risk Cervical Cancer: Pelvic Recurrence With Simple vs Radical Hysterectomy
As reported by Marie Plante, MD, and colleagues in The New England Journal of Medicine, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in terms of pelvic recurrence in women with low-risk cervical cancer. Simple hysterectomy was associated with a reduced...
FDA Approves Denosumab Biosimilars
On March 5, the the U.S. Food and Drug Administration (FDA) approved Jubbonti (denosumab-bbdz, 60 mg/1 mL injection), as an interchangeable biosimilar to U.S.-licensed Prolia (denosumab), and Wyost (denosumab-bbdz, 120 mg/1.7 mL [70 mg/mL] injection), as an interchangeable biosimilar to...
Medical Debt May Be Associated With Poorer Health Status and Survival Outcomes at U.S. County Level
Medical debt is associated with worse health status, more premature deaths, and higher mortality rates in the United States, according to a recent cross-sectional study published by Han et al in JAMA Network Open. Background“Patients are increasingly burdened by high out-of-pocket costs for health...
Could Smoking-Related DNA Changes Reflect Differential Lung Cancer Risks by Race and Ethnicity?
Investigators may have uncovered differential associations between smoking and DNA methylation across various racial and ethnic groups, according to a recent study published by Huang et al in the American Journal of Human Genetics. The findings could lead to the development of new strategies to...
